Full-Time
Senior Devops Platform Engineer
Software Product Engineering
Posted on 8/30/2025
Lilly USA
10,001+ employees
Global pharmaceutical company developing medicines
No salary listed
Bengaluru, Karnataka, India
In Person
 DevOps & Infrastructure (1) |
|---|
- Bachelor's degree in Computer Science, Software Engineering, or a related field.
- 8 to 11 years of professional experience in the industry.
- 4+ years of development experience in Amazon Web Services, GitHub Actions, Containers, Kubernetes, and high performance computing.
- 3+ years hands-on experience in building DevOps pipelines for automating, building, and deploying Microservice Applications, APIs, and Non-container Artifacts.
- 4+ years hands-on GitHub Actions, ArgoCD, Helm Charts.
- 4+ years hands-on experience with CI/CD technologies including Microservices, Terraform, and pipeline creation/management (e.g., Github, Artifactory/JFROG, etc).
- Experience with observability tools like Prometheus, Grafana.
- Experience with the Software Development Life Cycle (SDLC) and the practices i.e (Testing, Code Reviews, Code Coherence, use of multiple frameworks/libraries).
- Hands-on developer knowledge of Infrastructure-as-Code and associated technologies.
- Knowledge of IaaS and PaaS offerings in AWS or Azure or GCP and a willingness to upskill as the company’s adoption grows.
- Experience developing scripts or automating tasks using languages such as Bash, Powershell, Python, etc.
- Advanced knowledge of application, data, and infrastructure architecture disciplines.
- Extensive experience in container-based technologies.
- Proven ability to design, develop, and implement scalable, elastic microservice based platforms.
- Ability to lead a team in resolving technical issues through debugging, research, and investigation.
- Experience working with Git, specifically working in a team which adopts modern Git practices.
- Work as a Lead Engineer specializing in Kubernetes and Amazon Web Services on a team of full stack software developers to develop and maintain software platforms and DevOps processes.
- Guide and collaborate with internal application teams to deploy solutions on a custom Cloud Deployment Platform.
- Improve and maintain reusable pipeline templates and patterns for automated deployment of cloud infrastructure and code.
- Develop and support high-quality automation workflows inside and outside the cloud platform that are appropriate for business and technology strategies.
- Work with software developers and operations engineers to improve the software delivery process.
- Stay up to date on the latest DevSecOps practices and technologies.
- Strive to provide internal customers with excellent customer service.
- Effectively contribute to the communication of platform health, risks, and issues to the program partners, stakeholders, and management teams.
- Independently resolve conflicts between prioritization and scope.
- Be a self-starter, able to come up with solutions to problems and complete those solutions while coordinating with other teams.
- Develop secure, quality code and associated tests. Perform code reviews and participate in pair programming sessions.
- Work in a modern Agile environment to deliver customer value with regular cadence.
- Any AWS Certification (preferably DevOps)
- Any Agile Certification (preferably scaled Agile).
- Strong understanding of cloud infrastructure and architecture best practices.
- Experience in working on Code Quality SAST and DAST tools like SonarQube/SonarCloud, Checkmarx, and Snyk.
- Strong teamwork, self-management, bias for action, & problem-solving abilities.
- Excellent proactive oral and written communication skills.
Lilly is a global pharmaceutical company that discovers, develops, and sells prescription medicines to improve health outcomes. It grows its portfolio through extensive research and development, then manufactures and distributes drugs worldwide to healthcare providers who prescribe them to patients. Lilly’s products span diabetes, cancer, immunology, pain management, and other serious conditions, including diabetes treatments tirzepatide and dulaglutide. The company emphasizes safety, efficacy, and ethical practices, and protects its products from counterfeiting while partnering with organizations such as Team USA. Its approach relies on rigorous R&D, strong manufacturing, and a global distribution network to bring medicines to patients. Lilly’s goal is to help people live better lives by delivering reliable medical solutions through a global, ethical, and quality-focused operation.
Company Size
10,001+
Company Stage
IPO
Headquarters
Indianapolis, Indiana
Founded
1876
Simplify's Take
What believers are saying
- Foundayo broadens obesity access with oral dosing and no dietary timing requirements.
- The 2027 Lebanon API plant secures tirzepatide, Foundayo, and retatrutide supply.
- China reimbursement and expanding international access can extend Mounjaro's growth beyond the United States.
What critics are saying
- Novo Nordisk's Wegovy and Ozempic directly pressure pricing, formulary access, and share.
- Foundayo's hepatic-failure report invites labeling scrutiny and slows prescriber adoption after launch.
- Tirzepatide concentration makes any manufacturing slip or safety issue immediately hit most company growth.
What makes Lilly USA unique
- Tirzepatide powered Mounjaro and Zepbound to $36.5 billion in FY2025.
- Lilly opened its first genetic medicine facility in Lebanon, Indiana on May 6, 2026.
- Dave Ricks plans three to four new medicine launches annually for a decade.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Lilly USA who can refer or advise you
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Flexible Work Hours
Wellness Program
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -4%2 year growth
↓ -4%Eli Lilly has announced an additional $4.5 billion investment in its Lebanon, Indiana facilities, bringing its total investment in the LEAP Innovation and Research district to $21 billion. The company opened its first Advanced Therapies site on Wednesday, marking the first operational facility in the 9,000-acre LEAP district. The new funding will support Lilly's Advanced Therapies laboratory and an active pharmaceutical ingredient facility expected to open in 2027. The Advanced Therapies site is Lilly's first dedicated genetic medicine manufacturing facility, focusing on molecular-level research for diseases including Alzheimer's, Parkinson's and ALS. Lilly is developing three facilities across 800 acres in LEAP, including a Medicine Foundry. The Advanced Therapies facility aims to accelerate delivery of breakthrough genetic medicines to patients.
Unlocking AI innovation in finance medicine and music. Published on May 05, 2026 GENETIC MEDICINE REVOLUTION: AI AND BIOTECH JOIN FORCES. In a groundbreaking partnership, Lilly and AI-driven Profluent Bio are teaming up in a deal worth up to $2.25 billion to develop advanced DNA editing tools. Their goal? To create precise treatments for genetic conditions that currently lack effective solutions, using innovative AI models to design enzymes that can target multiple mutations in the genome. This collaboration aims to unlock the "holy grail" of genetic medicine through kilobase-scale DNA editing. This matters because it could transform how AI Software Services treat genetic diseases, offering hope to millions who suffer from conditions deemed untreatable. The tools being developed are likely to be accessible, lowering barriers to entry in a field that has traditionally been expensive and exclusive. Imagine a startup that provides a platform for creators and developers to access these AI-driven genetic editing tools, enabling them to innovate and create personalized therapies. This could attract investors eager to support the next wave of medical breakthroughs!
French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly. The ANSM fined Novo Nordisk 783,838 euros regarding adverts for Wegovy and also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." * Updated On May 4, 2026 at 05:54 PM IST Paris: France's medicine safety agency ANSM said Monday it had imposed fines on pharmaceutical firms Novo Nordisk and Eli Lilly over their advertising campaigns on obesity. The agency fined on Novo Nordisk France 1.78 million euros ($2.08 million) - a million relating to adverts promoting its Saxenda drug and 783,838 euros regarding adverts for Wegovy weight management medication for treating obesity. The ANSM also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." French laws prohibit any advertising to the general public of the treatments. The national medicines regulator said that the fines aimed to "prevent any communication likely to promote the use of drug treatment as the principal response to obesity, to encourage the public to request this treatment from a healthcare professional or seek to obtain it themselves." Event. * Fri, 24 Jul 2026 * Le Meridien, Hyderabad The ANSM said the advertising campaigns were "likely to mislead the public in a context marked by extensive media coverage" as well as what it termed growing inappropriate use of medications which activate certain hormones in order notably to reduce appetite,and aid weight loss. In a statement to AFP, Novo Nordisk France said it "strongly contests" the ANSM's finding, adding it is "exploring all possible appeal avenues against this decision". Lilly France said it noted ANSM's decision, while stating it believes its awareness campaign entitled "Obesity is a sick person's problem" from a year ago was "in line with the framework applicable to communications relating to human health". According to a French study published in 2024, around 18 percent of the French population - equivalent to some ten million people - are obese.
The FDA is requesting additional safety data from Eli Lilly for its weight loss pill Foundayo, including information on potential heart and liver problems, according to the approval letter published Tuesday. The agency wants more data on risks including heart attacks, strokes, drug-induced liver injuries and delayed stomach emptying. Foundayo, approved this month under a fast-track pilot programme, is the second oral GLP-1 to reach market after Novo Nordisk's Wegovy pill. The FDA is also asking Lilly to collect thyroid cancer risk data for at least 15 years. The requests are considered routine for newly approved drugs, particularly for orforglipron, Foundayo's active ingredient, which has less safety data than older GLP-1s. Lilly must also establish registries tracking children with obesity and pregnancy outcomes.
Vasa Therapeutics, a clinical-stage biopharmaceutical company, has partnered with Eli Lilly to use Lilly TuneLab, an AI-enabled drug discovery platform that provides access to models trained on Lilly's proprietary research data. Vasa will use the platform to accelerate development of its CAMKII delta inhibitor, which is planned for Phase 1 clinical trials in 2027. The company's VS-041 is currently in a proof-of-mechanism trial for heart failure, whilst VS-214 is on track for first-in-human trials in 2026. The platform uses federated learning, allowing companies to access Lilly's AI models whilst maintaining data privacy. Vasa will contribute its own experimental datasets to support the platform's improvement. The company focuses on developing therapies for cardiovascular, neuromuscular and age-related disorders.